Abbvie Inc ABBV:NYSE

Last Price$153.50NYSE Previous Close - Last Trade as of 7:00PM ET 5/13/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$153.60 (1)
Ask (Size)$154.25 (1)
Day Low / HighN/A - N/A
Volume4.0 K

AbbVie Receives FDA Second Indication Approval for Skyrizi to Treat Adults with Active Psoriatic Arthritis

4:40PM ET 1/21/2022 MT Newswires
AbbVie (ABBV) said Friday that the US FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis.

According to the company, the approval will expand the use of Skyrizi to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading the development and commercialization of Skyrizi globally.

Shares were flat in the after-hours session.

Price: 132, Change: +0.02, Percent Change: +0.02